Key facts
- This page summarizes Shimon Citron's Form 3 filing for Artemis Therapeutics, Inc..
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 12 Aug 2022, 16:05.
Shimon Citron - 30 Jun 2022 Form 3 Insider Report for Artemis Therapeutics, Inc.
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 30 Jun 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Shimon Citron
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Shimon Citron filed Form 3 for Artemis Therapeutics, Inc. on 12 Aug 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATMS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 15,665,690
- Date
- 30 Jun 2022
- Ownership
- Direct
ATMS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,443,793
- Date
- 30 Jun 2022
- Ownership
- By Spouse
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATMS
holding
Derivative
Series D Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,772,000
- Exercise price
- Footnotes
- F2, F3, F4
ATMS
holding
Derivative
Series D Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jun 2022
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 21,848,400
- Exercise price
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These securities are beneficially owned by Mr. Citron's spouse, Sigal Citron. Mr. Citron disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Footnote F2
Upon the Issuer's increase of its authorized shares of Common Stock, expected in September 2022, all shares of Series D Preferred Stock will automatically convert into the Issuer's Common Stock.
Footnote F3
The Series D Preferred Stock has no expiration date.
Footnote F4
Each share of Series D Preferred Stock will convert into 600 shares of the Issuer's Common Stock.